Plus Therapeutics' REYOBIQ Shows Promising Survival Data in Leptomeningeal Metastases Trial
Event summary
- Plus Therapeutics presented Phase 1 ReSPECT-LM trial data for REYOBIQ at the 2026 AANS Annual Scientific Meeting, showing median overall survival of ~9 months in leptomeningeal metastases patients.
- The trial demonstrated high target-to-off-target radiation delivery ratio (>100:1) and emerging immunomodulation effects, including CD8+ T cell activation.
- REYOBIQ's Phase 1 Multiple Dose trial is ongoing at UT Health San Antonio, focusing on safety and tolerability in patients with leptomeningeal metastases from various solid tumors.
- The company has secured significant funding for its trials, including a $17.6M grant from CPRIT for ReSPECT-LM and a $3M grant from the DoD for ReSPECT-PBC.
The big picture
Plus Therapeutics' positive Phase 1 data for REYOBIQ in leptomeningeal metastases positions the company as a key player in developing targeted radiotherapeutics for CNS cancers. The favorable safety and survival outcomes, along with emerging immunomodulation effects, highlight the potential for REYOBIQ to address a critical unmet need in this devastating condition. The ongoing multiple dose trial and strategic funding from CPRIT and the DoD underscore the clinical and financial momentum behind the program.
What we're watching
- Clinical Validation
- Whether the emerging immunomodulation data for REYOBIQ will support future combination therapy strategies with immunotherapies.
- Regulatory Pathway
- The pace at which Plus Therapeutics can advance REYOBIQ into later-stage clinical development based on these Phase 1 results.
- Competitive Positioning
- How REYOBIQ's targeted radiation delivery and safety profile will differentiate it in the leptomeningeal metastases treatment landscape.
Related topics